Results 61 to 70 of about 126,024 (329)

Sorafenib induces ferroptosis by promoting TRIM54-mediated FSP1 ubiquitination and degradation in hepatocellular carcinoma

Hepatology Communications, 2023
Background: Ferroptosis is a unique form of regulated cell death that provided a new opportunity for cancer therapy. Ferroptosis suppressor protein 1 (FSP1) is a key regulator in the NAD(P)H/FSP1/CoQ10 antioxidant system, which sever as an oxide redox ...
Man-ru Liu, Ce Shi, Qiu-Ya Song, Meng-jie Kang, Xin Jiang, Hui Liu, Dongsheng Pei   +6 more
semanticscholar   +1 more source

Herb-Drug Interaction between the Traditional Hepatoprotective Formulation and Sorafenib on Hepatotoxicity, Histopathology and Pharmacokinetics in Rats

Molecules, 2017
Sorafenib has been used as a standard therapy for advanced hepatocellular carcinoma (HCC). In Asia, patients with HCC are potentially treated with the combination of sorafenib and Chinese herbal medicines to improve the efficiency and reduce the side ...
Chin-Tsung Ting, Yung-Yi Cheng, Tung-Hu Tsai   +2 more
doaj   +1 more source

Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib [PDF]

, 2016
ARQ 197-215 was a randomized placebo-controlled phase II study testing the MET inhibitor tivantinib in second-line hepatocellular carcinoma (HCC) patients. It identified tumor MET as a key biomarker in HCC.
Abbadessa, Giovanni, Borbath, Ivan, Daniele, Bruno, De Toni, Enrico N, Gasbarrini, Antonio, Lamar, Maria E, Lencioni, Monica, Miles, Steven, Personeni, Nicola, Porta, Camillo, Rimassa, Lorenza, Salvagni, Stefania, Santoro, Armando, Schwartz, Brian E, Shuster, Dale, Trojan, Jörg, Van Laethem, Jean-Luc, Van Vlierberghe, Hans, Wang, Yunxia, Weiss, Alan   +19 more
core   +4 more sources

Remodeling Serine Synthesis and Metabolism via Nanoparticles (NPs)‐Mediated CFL1 Silencing to Enhance the Sensitivity of Hepatocellular Carcinoma to Sorafenib

Advancement of science, 2023
Tyrosine kinase inhibitors represented by sorafenib are the first‐line treatment for hepatocellular carcinoma (HCC), but the low response rate of HCC patient has become a clinical pain‐point.
Senlin Li, Lei Xu, Guo Wu, Ziqi Huang, Linzhuo Huang, Fengqian Zhang, Chunfang Wei, Q. Shen, Rong Li, Lei Zhang, Xiaoding Xu   +10 more
semanticscholar   +1 more source

Patient‐Reported Outcomes with Selpercatinib Treatment Among Patients with RET‐Mutant Medullary Thyroid Cancer in the Phase I/II LIBRETTO‐001 Trial

The Oncologist, EarlyView., 2021
Abstract Background Medullary thyroid cancer (MTC) standard of care includes multikinase inhibitors (MKIs), which can exacerbate disease‐related diarrhea, primarily because of non‐RET kinase inhibition. We report diarrhea and other patient‐reported outcomes (PROs) with selpercatinib, a highly selective RET inhibitor, among patients with RET‐mutant MTC ...
Lori J. Wirth, Bruce Robinson, Valentina Boni, Daniel S.W. Tan, Caroline McCoach, Erminia Massarelli, Lisa M. Hess, Min‐Hua Jen, Jennifer Kherani, Elizabeth Olek, Vivek Subbiah   +10 more
wiley   +1 more source

Optimizing survival outcomes with post-remission therapy in acute myeloid leukemia. [PDF]

, 2019
Optimization of post-remission therapies to maintain complete remission and prevent relapse is a major challenge in treating patients with acute myeloid leukemia (AML).
Chan, Steven M, Daver, Naval G, Jonas, Brian A, Medeiros, Bruno C, Pollyea, Daniel A   +4 more
core   +1 more source

Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial

Gut, 2019
Objective This trial compared the efficacy and safety of transarterial chemoembolisation (TACE) plus sorafenib with TACE alone using a newly established TACE-specific endpoint and pre-treatment of sorafenib before initial TACE.
M. Kudo, K. Ueshima, M. Ikeda, T. Torimura, N. Tanabe, H. Aikata, N. Izumi, T. Yamasaki, S. Nojiri, K. Hino, H. Tsumura, T. Kuzuya, N. Isoda, K. Yasui, Hajime Aino, A. Ido, Naoto Kawabe, K. Nakao, Y. Wada, O. Yokosuka, K. Yoshimura, T. Okusaka, J. Furuse, N. Kokudo, K. Okita, P. Johnson, Y. Arai   +26 more
semanticscholar   +1 more source

Sorafenib-induced acute pancreatitis

Journal of Medical Sciences, 2014
Sorafenib was approved in 2005 for the treatment of metastatic renal cell carcinoma and advanced hepatocellular carcinoma (HCC). Acute pancreatitis is a side-effect of sorafenib usage. We present a patient with advanced HCC who presented with acute Grade
Han-En Wang, Chun-Ting Chen, Hsin-Hung Huang   +2 more
doaj   +1 more source

Nrf2 signaling promotes cancer stemness, migration, and expression of ABC transporter genes in sorafenib-resistant hepatocellular carcinoma cells.

PLoS ONE, 2021
Background and aimAs a multiple tyrosine kinase inhibitor, sorafenib is widely used to treat hepatocellular carcinoma (HCC), but patients frequently face resistance problems.
Luping Gao, Yuji Morine, Shinichiro Yamada, Yu Saito, Tetsuya Ikemoto, Kazunori Tokuda, Chie Takasu, Katsuki Miyazaki, Mitsuo Shimada   +8 more
doaj   +1 more source

Glutathione Metabolism in Renal Cell Carcinoma Progression and Implications for Therapies [PDF]

, 2019
A significantly increased level of the reactive oxygen species (ROS) scavenger glutathione (GSH) has been identified as a hallmark of renal cell carcinoma (RCC). The proposed mechanism for increased GSH levels is to counteract damaging ROS to sustain the
Meierhofer, David, Xiao, Yi
core   +2 more sources